Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

What pushed Israel out of herd immunity? Modeling COVID-19 spread of Delta and Waning immunity

View ORCID ProfileHilla De-Leon, View ORCID ProfileDvir Aran
doi: https://doi.org/10.1101/2021.09.12.21263451
Hilla De-Leon
1INFN-TIFPA Trento Institute of Fundamental Physics and Applications, Italy
2European Centre for Theoretical Studies in Nuclear Physics and Related Areas (ECT*), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hilla De-Leon
  • For correspondence: hdeleon@ectstar.eu
Dvir Aran
3Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
4The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel
5Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dvir Aran
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Following a successful vaccination campaign at the beginning of 2021 in Israel, where approximately 60% of the population were vaccinated with an mRNA BNT162b2 vaccine, it seemed that Israel had crossed the herd immunity threshold (HIT). Nonetheless, Israel has seen a steady rise in COVID-19 morbidity since June 2021, reaching over 1,000 cases per million by August. This outbreak is attributed to several events that came together: the temporal decline of the vaccine’s effectiveness (VE); lower effectiveness of the vaccine against the current Delta (B.1.617.2) variant; highly infectiousness of Delta; and temporary halt of mandated NPIs (non-pharmaceutical interventions) or any combination of the above. Using a novel spatial-dynamic model and recent aggregate data from Israel, we examine the extent of the impact of the Delta variant on morbidity and whether it can solely explain the outbreak. We conclude that both Delta infectiousness and waning immunity could have been able to push Israel below the HIT independently, and thus, to mitigate the outbreak effective NPIs are required. Our analysis cautions countries that once vaccines’ will wane a highly infectious spread is expected, and therefore, the expected decline in the vaccine’s effectiveness in those countries should be accompanied by another vaccination campaign and effective NPIs.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

DA is supported by the Azrieli Faculty Fellowship and is a Deloro Fellow

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All the data is available online

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† E-mail: dviraran{at}technion.ac.il

  • Figure 2 revised

Data Availability

All the data in available on: 1.https://datadashboard.health.gov.il/COVID-19/general 2. https://github.com/dancarmoz/israel_moh_covid_dashboard_data 3. https://ourworldindata.org/coronavirus

https://ourworldindata.org/coronavirus

https://data.gov.il/dataset/covid-19

https://github.com/dancarmoz/israel_moh_covid_dashboard_data

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
What pushed Israel out of herd immunity? Modeling COVID-19 spread of Delta and Waning immunity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
What pushed Israel out of herd immunity? Modeling COVID-19 spread of Delta and Waning immunity
Hilla De-Leon, Dvir Aran
medRxiv 2021.09.12.21263451; doi: https://doi.org/10.1101/2021.09.12.21263451
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
What pushed Israel out of herd immunity? Modeling COVID-19 spread of Delta and Waning immunity
Hilla De-Leon, Dvir Aran
medRxiv 2021.09.12.21263451; doi: https://doi.org/10.1101/2021.09.12.21263451

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1774)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10824)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2962)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1935)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (294)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12530)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2815)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (258)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (339)
  • Psychiatry and Clinical Psychology (2650)
  • Public and Global Health (5386)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (293)
  • Sports Medicine (279)
  • Surgery (328)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (127)